Skip to content
Science

Scientists warn that greener drug design is urgently needed to address environmental pollution

Monash University 2 mins read
Image credit - Peter Hermes Furian (iStock)

The widespread contamination of ecosystems with pharmaceuticals poses a serious and growing threat to biodiversity, ecosystem services and public health. 

Urgent action is needed to design greener drugs that maintain efficacy while minimising environmental impact, according to an international study published in Nature Sustainability and involving Monash University researchers.

“In our increasingly medicated world, pharmaceuticals are essential to modern healthcare, having revolutionised disease prevention and treatment,” said co-lead author of the study Dr Michael Bertram, an Assistant Professor at the Swedish University of Agricultural Sciences, Umeå, Sweden, who also holds an adjunct position at the Monash University School of Biological Sciences.

“However, our growing dependence on pharmaceuticals comes at a major cost,” he said.

“Discharges during drug production, use and disposal have led to global contamination of ecosystems with mixtures of pharmaceuticals and their breakdown products. In fact, when patients take medicines, only a portion of those drugs are absorbed by the body, with the remainder being excreted and often released directly into the environment.”

Pharmaceutical contaminants have now been detected in environmental samples and the tissues of wildlife across all continents on Earth, including Antarctica. The pervasive spread of these contaminants, which are also found in groundwater used for drinking water, has led to the inclusion of several pharmaceuticals as priority substances in the new update to the European Water Framework Directive, a Europe-wide wastewater regulation.

“Evidence has been mounting for decades that trace concentrations of pharmaceutical pollutants and their mixtures can cause severe developmental, physiological, morphological, and behavioural changes in wildlife,” said co-author of the study Professor Bob Wong, from the Monash University School of Biological Sciences.

“For example, male fish exposed to estrogens found in the birth control pill exhibit feminisation and reproductive failure, leading to population collapse, while vultures exposed to anti-inflammatory drugs have undergone severe population crashes due to toxic effects,” he said.

“The impacts of pharmaceutical pollutants can have cascading effects on the ecology and evolution of wildlife populations and communities, potentially causing population declines and local extinctions.”

Pharmaceutical pollution poses threats to both wildlife and humans, such as the release of antibiotics into the environment promoting the spread of antibiotic resistance genes. 

This issue is exacerbated by other anthropogenic pressures, including climate change, habitat destruction and invasive species. Interactions between chemical pollutants and these other stressors can be additive or synergistic, further endangering biodiversity and ecosystem services.

“To address drug pollution, we urgently need to implement strategies to minimise environmental impacts across the entire pharmaceutical life cycle,” said study co-author Dr Lauren May, from the Monash Institute of Pharmaceutical Sciences.

“This includes promoting sustainable prescribing practices, increasing public awareness about the environmental impact of medicines, enhancing wastewater treatment processes, and actively pursuing eco-friendly drug design,” she said.

“Key to tackling this issue at its source is the design of greener pharmaceuticals that degrade more rapidly and completely in the environment,” says co-author Dr Manuela Jorg, also from the Monash Institute of Pharmaceutical Sciences.

The researchers say that greener pharmaceuticals should be designed for environmental degradation. The study argues that regulatory agencies should set standardised cut-off values for environmental persistence of pharmaceuticals, to limit the presence of harmful drugs in the environment. 

Media enquiries:

Silvia Dropulich
Marketing, Media and Communications Manager, Monash Science
T: +61 3 9902 4513 M: +61 435 138 743
Email: silvia.dropulich@monash.edu

Hande Cater
Media and Communications Manager, Monash University
M: +61 456 428 906
Email: hande.cater@monash.edu

General media enquiries:

Monash Media
T: +61 (0) 3 9903 4840
E: media@monash.edu
For more Monash media stories, visit our news and events site 

Media

More from this category

  • Science
  • 18/06/2024
  • 22:08
Takeda Pharmaceutical Company Limited

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

Favorable Findings fromthe Longest Public Clinical Study in CIDP Support HYQVIA as an Effective Long-Term Treatment Option for Maintaining Stable Disease Course in CIDP…

  • Contains:
  • Medical Health Aged Care, Science
  • 18/06/2024
  • 12:30
WEHI

WEHI spinout company set to revolutionise homegrown cancer treatments

Australia has cemented its role in becoming a major player in the next-generation of medicines with the launch of Ternarx – a globally competitive biotechnology company dedicated to finding new treatments for hard to treat cancers. The WEHI spinout is the first of its kind in Australia dedicated to developing targeted protein degrader medicines and technology, a powerful new tool for destroying disease-causing proteins that cannot be targeted by conventional drugs. Ternarx, which is backed by $15 million in funding from the Medical Research Future Fund’s (MRFF) Frontier Health and Medical Research initiative and by support from WEHI, has been…

  • Contains:
  • Science
  • 18/06/2024
  • 02:37
Nexeo Plastics

GPD Companies, Inc. Names Kurt Schuering as President and Chief Executive Officer

Paul Tayler to Retire and Remain on Board of DirectorsTHE WOODLANDS, TX / ACCESSWIRE / June 17, 2024 / GPD Companies, Inc. ("GPD"), an affiliate of One Rock Capital Partners, LLC ("One Rock"), today announced the appointment of Kurt Schuering as President and CEO, effective June 24, 2024. Paul Tayler will retire from his role as President and CEO and remain on GPD's Board of Directors. Schuering brings nearly 30 years of experience in the plastics industry and a proven track record of success, making him the ideal candidate to lead GPD into its next phase of growth and innovation.…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.